Avtor/Urednik		Cvetinović, Nataša; Isaković, Andjelka M.; Lainščak, Mitja; Düngen, Hans-Dirk; Marković Nikolić, Nataša; Lončar, Goran
Naslov		Procalcitonin in heart failure
Tip		članek
Vol. in št.		Letnik 11, št. 10
Leto izdaje		2017
Obseg		str. 893-903
ISSN		1752-0363 - Biomarkers in medicine
Jezik		eng
Abstrakt		Although procalcitonin (PCT) was evaluated for the first time in the setting of heart failure (HF) in 1999, its utility in HF patients is still under examination. Patients with HF have significantly higher plasma PCT concentrations than healthy subjects and PCT levels are associated with severity of HF. It has been confirmed that higher levels of PCT are associated with worse outcomes, such as increased mortality and higher rate of rehospitalization, in HF patients with no evidence of infection. Furthermore, it has been approved that PCT-guided antibiotic treatment in HF patients reduces duration of antibiotic therapy and improves outcomes. This review summarizes current evidence from the published literature of the usefulness and limitations of PCT as a biomarker in HF.
Proste vsebinske oznake		biološki označevalci srčno popuščanje infekcije prokalcitonin biomarker heart failure infection procalcitonin